Managing Myeloma
- 2016-09-13 - Multiple Myeloma Research Foundation : (MMRF) and Memorial Sloan Kettering (MSK) Cancer Center
- 2016-09-06 - Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug
- 2016-08-17 - Janssen Submits Application To U.S. FDA To Expand Indication For Daratumumab (DARZALEX®)
- 2016-08-09 - MMRF, University of Michigan to Begin Personalized Multiple Myeloma Profiling Initiative
- 2016-07-28 - AbbVie Announces Initiation Of Phase 3 Study Of Venetoclax In Patients With Relapsed Or Refractory Multiple Myeloma
- 2016-07-25 - Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma
- 2016-07-22 - New Multiple Myeloma Drug Interferes With Routine Testing Prior to a Transfusion
- 2016-06-14 - UofL leads first research team to identify AF1q protein associated with multiple myeloma, extramedullary disease
- 2016-06-07 - Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
- 2016-05-23 - Genmab Announces European Conditional Marketing Authorization for DARZALEX® (daratumumab) for Multiple Myeloma
- 2016-05-18 - Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
- 2016-05-16 - Drug makers fuming at ‘overpriced’ values placed on their myeloma drugs
- 2016-05-11 - Bristol-Myers Squibb, AbbVie's Empliciti approved in Europe for multiple myeloma
- 2016-05-06 - Independent group finds multiple myeloma drugs too costly in U.S.
- 2016-05-06 - ICER Releases Evidence Report on Treatments for Multiple Myeloma